TriSalus received FDA 510(k) clearance for TriNav Advance and shares rose about 5.8%, which improves its ability to sell that product in the U.S.
The FDA 510(k) clearance for TriNav Advance clears a regulatory step that lets TriSalus offer that device in the U.S. This improves the company's ability to sell the product and supports future revenue. The stock's 5.8% jump shows investors view the clearance as positive, though the company remains below its 52-week high and is a small market cap firm.
Lakefront Biotherapeutics was upgraded by RBC Capital and its price target was raised from $26 to $45, which signals stronger analyst support for the company's outlook.
Editas Medicine was upgraded from Neutral to Buy with a $5 price target, indicating an analyst expects better performance than before.
Bandwidth's shares rose about 6.4% to $62.18 today, but the story reports no company-specific news beyond the price move, so it does not change the company's outlook here.
Maze Therapeutics had an analyst reaffirm an Outperform rating and keep a $48 price target, which signals continuing analyst confidence in the company.
Moderna had three abstracts accepted for presentation at ESMO 2026 about its individualized neoantigen therapy, which supports the company's scientific progress and pipeline value.
Follow TriSalus Life Sciences Inc (TLSI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TLSI